Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530493 | 0.93 | RAB9A (0.53) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL5855420 | 0.89 | PPARG (0.56) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL5856859 | 0.88 | PPARG (0.55) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL4888378 | 0.87 | RAB9A (0.62) | HPGDPPARGPPARAKDM4ELMNA | |
| SCHEMBL1981068 | 0.87 | PPARG (0.54) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL1436051 | 0.87 | PPARA (0.51) | SMN1; SMN2ALDH1A1PPARGPPARAKDM4E | |
| SCHEMBL1436227 | 0.87 | HSD17B10 (0.54) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL979145 | 0.87 | KDM4E (0.65) | HPGDPPARGPPARAKDM4ETARBP2 | |
| SCHEMBL4925692 | 0.86 | TP53 (0.52) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL5365528 | 0.86 | KDM4E (0.57) | SMN1; SMN2ALDH1A1POLBHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025054309-A1 | METHODS OF IDENTIFYING AND TREATING PATIENTS HAVING NEURODEGENERATIVE DISEASE BASED ON PLASMA BIOMARKER LEVELS | T3D THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025024308-A1 | METHODS OF TREATING ENDOTHELIAL CELL AND AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2004082601-A2 | METHOD OF TREATING DIABETES AND DIABETES-RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040171835-A1 | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-02 | — | — | US | disclosed |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040102439-A1 | Halogenobenzyl aminopropionic acid derivatives | TOAEIYO LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| US-20040087636-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-05-06 | — | — | US | disclosed |
| EP-1405848-A1 | TETRAHYDROQUINOLINE DERIVATIVE COMPOUND AND DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-6664281-B1 | Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC | 2003-11-20 | — | — | US | disclosed |
| EP-1354879-A1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1108713-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087636-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | SMN1; SMN2 4797/4885ALDH1A1 252/4885POLB 2953/4885 |
| US-20040102439-A1 | Halogenobenzyl aminopropionic acid derivatives | FABP4, SLC5A1, ALDH7A1 | SMN1; SMN2 4817/4885ALDH1A1 128/4885POLB 2769/4885 |
| US-20040171835-A1 | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | SREBF1, NR1H2, NR1H3 | SMN1; SMN2 4728/4885ALDH1A1 1494/4885POLB 2971/4885 |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | SMN1; SMN2 81/4885ALDH1A1 1138/4885POLB 1964/4885 |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | SREBF1, NR1H2, NR1H3 | SMN1; SMN2 4638/4885ALDH1A1 401/4885POLB 3227/4885 |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | PPARD, PPARA, PPARG | SMN1; SMN2 2027/4885ALDH1A1 384/4885POLB 1616/4885 |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | MAPT, APP, IAPP | SMN1; SMN2 1943/4885ALDH1A1 1679/4885POLB 4035/4885 |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | SMN1; SMN2 4523/4885ALDH1A1 51/4885POLB 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.